Back to search results

Neuroblastoma Biology Study

This study is gathering information about neuroblastoma, a type of cancer that forms in nerve tissue. Researchers want to understand more about neuroblastoma cells to find better treatments and prevent the cancer from returning. They will collect and store samples of blood, bone marrow, and tumor tissue from people with neuroblastoma. They will also collect medical information and scans. This information will help scientists study the characteristics of neuroblastoma cells and find better ways to detect and measure the cancer's response to treatment. You may be able to join if you are 31 days old or older and have been diagnosed with high-risk neuroblastoma.

Study design
This is an observational study aiming to enroll 1000 participants. It involves collecting and storing biological samples and clinical data.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01587300

Neuroblastoma Biology Study

Recruiting
Not specifiedAges 31–99Observational
New Approaches to Neuroblastoma Therapy Consortium
~1,000 participants
Updated 2026-03-23 on ClinicalTrials.gov

At a glance

Recruiting sites
13 of 17 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring

A primary outcome measure isn't published for this study.

Conditions

Neuroblastoma

Explore related trials

Neuroblastoma

Where it's being run

17 sites across 13 states
California3
Ohio2
Texas2
Colorado1
Georgia1
Illinois1
Massachusetts1
Michigan1

Study leadership

  • Shahab Asgharzadeh, MD · STUDY_CHAIR · Children's Hospital Los Angeles

Who to contact

Araz Marachelian, MD
[email protected]
323-361-5687
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients must be greater than or 31 days of age.
Patients must have had a diagnosis of high risk neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.
All patients with refractory or recurrent high risk neuroblastoma at NANT institutions are eligible regardless of disease status (including no measurable or evaluable tumor) as long as they undergo a disease evaluation and appropriate samples are submitted.
Additionally, all patients with high risk neuroblastoma without relapse treated at a NANT institution are eligible if undergoing a disease evaluation, as long as Children's Oncology Group specimens are prioritized.